{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:31:35Z","timestamp":1793694695281,"version":"4.5.1"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.109664","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:18:05Z","timestamp":1791501485000},"page":"109664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vivo fate-guided design of efficient delivery systems for PROTACs: From molecular rationales to clinical progress"],"prefix":"10.1016","volume":"233","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7196-0103","authenticated-orcid":false,"given":"Yuling","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenJun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.109664_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2026.217834","article-title":"Design strategies and recent advances in activatable small molecule therapeutics","volume":"559","author":"Garcia","year":"2026","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib2","first-page":"265","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy, Nature reviews","volume":"20","author":"Deborah","year":"2023","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib3","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Ke","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.chembiol.2021.03.007","article-title":"Identification and selectivity profiling of small-molecule degraders via multi-omics approaches","volume":"28","author":"S.N","year":"2021","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib5","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.scib.2026.02.048","article-title":"Targeting focal adhesion kinase: From molecular mechanisms to next-generation cancer therapeutics","volume":"71","author":"Chen","year":"2026","journal-title":"Sci. Bull."},{"key":"10.1016\/j.phrs.2026.109664_bib6","first-page":"181","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Mikl\u00f3s","year":"2022","journal-title":"Nat. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Brandon","year":"2021","journal-title":"Nat. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115922","article-title":"Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)","volume":"236","author":"Banerjee","year":"2026","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib9","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"M","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.109664_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Xiuyun","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib11","article-title":"Advancing Strategies for Proteolysis-Targeting Chimera Design","volume":"66","author":"Minglei","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib12","article-title":"Targeting Epigenetic Modulators Using PROTAC Degraders: Current Status and Future Perspective","volume":"63","author":"Thomas","year":"2022","journal-title":"Bioorg. & Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.109664_bib13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/med.21877","article-title":"Strategies for designing proteolysis targeting chimaeras (PROTACs)","volume":"42","author":"Shipeng","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib14","first-page":"12","article-title":"The PROTAC gold rush","volume":"40","author":"Ken","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2026.109664_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Chao","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2026.109664_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking PROTACs from discovery to the clinic","volume":"10","author":"Pike","year":"2025","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: An Emerging Therapeutic Modality in Precision Medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: A safety perspective","volume":"177","author":"Kevin","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109664_bib19","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1007\/s11172-022-3659-z","article-title":"PROTAC: targeted drug strategy. Principles and limitations","volume":"71","author":"A","year":"2022","journal-title":"Russ. Chem. Bull."},{"key":"10.1016\/j.phrs.2026.109664_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.109664_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"Ming","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.phrs.2026.109664_bib23","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib25","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2026.109664_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"PROTAC 2.0: Expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.phrs.2026.109664_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-026-01853-2","article-title":"Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems","author":"Yao","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2026.109664_bib28","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Yu","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Taavi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib30","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2020.38.15_suppl.3500","article-title":"First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and\/or abiraterone (ABI)","volume":"38","author":"Petrylak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib31","article-title":"The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"S.L","year":"2021","journal-title":"CANCER Res"},{"key":"10.1016\/j.phrs.2026.109664_bib32","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/ijms22042124","article-title":"An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer","volume":"22","author":"M.M","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.109664_bib33","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1021\/acs.jmedchem.9b01393","article-title":"Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands","volume":"62","author":"Xin","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib34","article-title":"Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer","volume":"64","author":"Xin","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib35","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Kanak","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.109664_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400267","article-title":"Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy","volume":"19","author":"Jin","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2026.109664_bib37","article-title":"Discovery of estrogen receptor \u03b1 targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment","volume":"137","author":"Baohua","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib38","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.109664_bib40","article-title":"PROTACs technology for targeting non-oncoproteins: Advances and perspectives","volume":"114","author":"Chao","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib41","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Lindsay","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.109664_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41421-024-00711-x","article-title":"PROTAC for Bruton\u2019s tyrosine kinase degradation alleviates inflammation in autoimmune diseases","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell. Discov."},{"key":"10.1016\/j.phrs.2026.109664_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107624","article-title":"First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of ARV-102, a PROTAC LRRK2 degrader, in healthy volunteers","volume":"134","author":"Smits","year":"2025","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.phrs.2026.109664_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2026.109664_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Xin","year":"2020","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"G.M","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133680","article-title":"Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment","volume":"275","author":"Fan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phrs.2026.109664_bib48","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.phrs.2026.109664_bib49","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal\u2014An attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.109664_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70132","article-title":"Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment","volume":"131","author":"Anaya","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2026.109664_bib51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","article-title":"Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions","volume":"35","author":"Kamaraj","year":"2024","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ddr.22026","article-title":"Progress of small molecules for targeted protein degradation: PROTACs and other technologies","volume":"84","author":"HongYi","year":"2023","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.phrs.2026.109664_bib53","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.phrs.2026.109664_bib54","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1021\/acs.jmedchem.8b00506","article-title":"Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression","volume":"61","author":"Chong","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib55","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ymthe.2021.04.032","article-title":"Therapeutic targeting of RNA-binding protein by RNA-PROTAC","volume":"29","author":"Li","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib58","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Yonghui","year":"2018","journal-title":"Cell. Res."},{"key":"10.1016\/j.phrs.2026.109664_bib59","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acs.jmedchem.7b00237","article-title":"How Big Is Too Big for Cell Permeability?","volume":"60","author":"P\u00e4r","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib60","article-title":"Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity","volume":"66","author":"Chuanjie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib61","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"G.R","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","article-title":"Solution Conformations Shed Light on PROTAC Cell Permeability","volume":"12","author":"Yoseph","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.109664_bib63","article-title":"From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors","volume":"251","author":"Mladen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib64","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.122.001154","article-title":"Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders","volume":"51","author":"Volak","year":"2023","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.phrs.2026.109664_bib65","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib66","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug. Discov. Today. Technol."},{"key":"10.1016\/j.phrs.2026.109664_bib68","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. & Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.109664_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s42003-024-06238-x","article-title":"Metabolism-driven in vitro\/in vivo disconnect of an oral ER\u0251 VHL-PROTAC","volume":"7","author":"Hayhow","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2026.109664_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115033","article-title":"Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma","volume":"247","author":"Rishfi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib72","doi-asserted-by":"crossref","first-page":"23962","DOI":"10.1021\/acs.jmedchem.5c01271","article-title":"Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma","volume":"68","author":"Krols","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.109664_bib74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ejmech.2019.05.046","article-title":"Development of selective small molecule MDM2 degraders based on nutlin","volume":"176","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib75","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders","volume":"62","author":"Jiuling","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib76","article-title":"Design and Linkage Optimization of Ursane-Thalidomide-Based PROTACs and Identification of Their Targeted-Degradation Properties to MDM2 Protein","volume":"111","author":"Zhiwen","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib77","article-title":"Development of MDM2 Degraders Based on Ligands Derived from Ugi Reactions: Lessons and Discoveries","volume":"219","author":"Bo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib78","first-page":"152","article-title":"Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes","volume":"17","author":"James","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib79","article-title":"Discovery of IAP-Recruiting BCL-X L PROTACs as potent degraders across multiple cancer cell lines","volume":"199","author":"Xuan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib80","article-title":"VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives","volume":"227","author":"Chao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib81","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1038\/s41467-025-65478-5","article-title":"Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC","volume":"16","author":"Torodii","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib82","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1\u03b1 interaction","volume":"134","author":"L","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112769","article-title":"Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras","volume":"208","author":"Takwale","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib84","article-title":"Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands","volume":"82","author":"Weiyan","year":"2023","journal-title":"Bioorg. & Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib85","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib86","article-title":"Developments of CRBN-based PROTACs as potential therapeutic agents","volume":"225","author":"Chao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib87","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.109664_bib88","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd.2016.213","article-title":"Massachusetts, USA, DNA-encoded chemistry: enabling the deeper sampling of chemical space","volume":"16","author":"Goodnow","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.109664_bib89","article-title":"Bispecific Estrogen Receptor \u03b1 Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening","volume":"64","author":"S","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib91","article-title":"Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4","volume":"65","author":"K","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib92","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1182\/blood-2025-7852","article-title":"Proteolysis-targeting chimera (PROTAC) targeting bruton tyrosine kinase (BTK) degradation for cancer therapy in mantle cell lymphoma","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.109664_bib93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41392-025-02172-4","article-title":"Breaking down KRAS: small-molecule degraders for cancer therapy","volume":"10","author":"Kos","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib94","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood-2025-3020","article-title":"Inhibition of platelet kinase signaling and scaffolding activities with small molecule proteolysis-targeting chimeras (PROTACs)","volume":"146","author":"Choi","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.109664_bib95","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3390\/molecules26092525","article-title":"Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog\u2013Thalidomide PROTACs","volume":"26","author":"Yeong","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.109664_bib96","article-title":"Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment","volume":"45","author":"JianJia","year":"2021","journal-title":"Bioorg. & Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib97","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"E","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.phrs.2026.109664_bib98","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease a systematic review","volume":"72","author":"Danko","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib99","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Weijin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.109664_bib100","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. & Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.109664_bib101","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras","volume":"2","author":"Honorine","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.phrs.2026.109664_bib102","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1021\/acschembio.8b00705","article-title":"Modulating PCAF\/GCN5 Immune Cell Function through a PROTAC Approach","volume":"13","author":"I","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding","volume":"14","author":"P","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib104","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity","volume":"62","author":"Hao","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer","volume":"62","author":"Xin","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib106","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acsmedchemlett.9b00219","article-title":"Targeting IRAK4 for Degradation with PROTACs","volume":"10","author":"Nunes","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.109664_bib107","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib108","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/anie.201914396","article-title":"Structure-Based Design of a Macrocyclic PROTAC","volume":"59","author":"Testa","year":"2020","journal-title":"Angew. Chem. (Int. Ed. Engl. )."},{"key":"10.1016\/j.phrs.2026.109664_bib109","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib110","article-title":"Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras","volume":"64","author":"A","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib111","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.chembiol.2021.03.005","article-title":"The role of reversible and irreversible covalent chemistry in targeted protein degradation","volume":"28","author":"Hannah","year":"2021","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib112","first-page":"359","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Kedra","year":"2011","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.phrs.2026.109664_bib113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib114","doi-asserted-by":"crossref","unstructured":"T.A. Bemis, J.J.L. Clair, M.D. Burkart, Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras, Journal of medicinal chemistry. 64 8042\u20138052.","DOI":"10.1021\/acs.jmedchem.1c00482"},{"key":"10.1016\/j.phrs.2026.109664_bib115","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1021\/acsmedchemlett.1c00368","article-title":"Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands","volume":"12","author":"Ale\u0161a","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.109664_bib116","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib117","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib118","doi-asserted-by":"crossref","first-page":"18082","DOI":"10.1021\/acs.jmedchem.1c01496","article-title":"Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib119","article-title":"Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy","volume":"137","author":"Zhang","year":"2025","journal-title":"Angew. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202306824","article-title":"Stimuli-Responsive PROTACs for Controlled Protein Degradation","volume":"135","author":"An","year":"2023","journal-title":"Angew. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib121","article-title":"First Orally Bioavailable Prodrug of Proteolysis Targeting Chimera (PROTAC) Degrades Cyclin-Dependent Kinases 2\/4\/6 in vivo","volume":"209","author":"Mingming","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib122","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00044-019-02485-4","article-title":"Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects","volume":"29","author":"Da","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.phrs.2026.109664_bib123","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2026.109664_bib124","article-title":"Light-Controllable PROTACs for Temporospatial Control of Protein Degradation & #13","volume":"9","author":"Jing","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib125","article-title":"Light: A Magical Tool for Controlled Drug Delivery","volume":"30","author":"Yu","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.phrs.2026.109664_bib126","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1002\/cbic.202000113","article-title":"Optochemical control of protein degradation","volume":"21","author":"Debasish","year":"2020","journal-title":"Chembiochem a Eur. J. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib127","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cmdc.202000249","article-title":"Controlling PROTACs with Light","volume":"15","author":"Verma","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2026.109664_bib128","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib129","first-page":"1","article-title":"Spatiotemporally controlled protein degradation via NIR-activatable PROTAC platform","author":"Wang","year":"2025","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib130","first-page":"145","article-title":"Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors","author":"Chunrong","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib131","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2017.01.004","article-title":"Radiotherapy for Cancer: Present and Future","volume":"109","author":"Allen","year":"2017","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib133","first-page":"114","article-title":"Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer","volume":"19","author":"Giulia","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib134","doi-asserted-by":"crossref","first-page":"18136","DOI":"10.1021\/jacs.9b08669","article-title":"Enzyme-Instructed Activation of Pro-protein Therapeutics In Vivo","volume":"141","author":"Chang","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2017.04.013","article-title":"Substrate mediated enzyme prodrug therapy","volume":"118","author":"Fejerskov","year":"2017","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib136","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2023.07.062","article-title":"Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy","volume":"361","author":"Jing","year":"2023","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib137","article-title":"Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation","volume":"145","author":"Mengyang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib138","article-title":"Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation","volume":"66","author":"Tao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib139","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-68771-z","article-title":"Reactive oxygen species-activated bioorthogonal chemistry in living systems enabled by boronate-caged dihydrotetrazines","volume":"17","author":"Ming","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117526","article-title":"Glutathione-responsive PROTAC for targeted degradation of ER\u03b1 in breast cancer cells","volume":"96","author":"Zhou","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2026.101328","article-title":"Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy","volume":"79","author":"An","year":"2026","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2026.109664_bib142","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib143","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib144","doi-asserted-by":"crossref","first-page":"eabq2216","DOI":"10.1126\/sciadv.abq2216","article-title":"Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras","volume":"8","author":"Cong","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2026.109664_bib145","article-title":"Tandem-Activatable PROTAC Prodrug for Tumor Biomarker-Driven Near-Infrared Opto-Proteolysis","volume":"64","author":"Lu","year":"2025","journal-title":"Angew. Chem. (Int. Ed. Engl. )."},{"key":"10.1016\/j.phrs.2026.109664_bib146","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"A","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib147","article-title":"An antibody-PROTAC conjugate targets BRD4\/c-Myc\/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer","volume":"7","author":"Gu","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.phrs.2026.109664_bib148","article-title":"situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy","volume":"295","author":"Hanhee","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.109664_bib149","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Mariana","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.109664_bib150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1389200224666230419090052","article-title":"Folate Targeting Peptide Conjugates for Inflammatory Response Suppression","volume":"24","author":"Ruff","year":"2023","journal-title":"Curr. Drug. Metab."},{"key":"10.1016\/j.phrs.2026.109664_bib151","article-title":"Folate targeting self-limiting hyperthermic nanoparticles for controlled photothermal therapy","volume":"11","author":"Sharon","year":"2023","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.phrs.2026.109664_bib152","first-page":"143","article-title":"Cancer Selective Target Degradation by Folate-Caged PROTACs","author":"Jing","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib153","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202415323","article-title":"MicroRNA-Triggered Programmable DNA-Encoded Pre-PROTACs for Cell-Selective and Controlled Protein Degradation","volume":"137","author":"Zhan","year":"2025","journal-title":"Angew. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib154","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41589-024-01719-w","article-title":"Engineering artificial non-coding RNAs for targeted protein degradation","volume":"21","author":"Cao","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.109664_bib155","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70301","article-title":"Nanoplatform-Based Delivery Systems for PROTACs","volume":"87","author":"Che","year":"2026","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.phrs.2026.109664_bib156","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","article-title":"Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles","volume":"330","author":"Chen","year":"2021","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib157","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","article-title":"Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer","volume":"15","author":"Saraswat","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2026.109664_bib158","article-title":"Glutathione-responsive PROTAC for targeted degradation of ER\u03b1 in breast cancer cells","volume":"96","author":"Zhili","year":"2023","journal-title":"Bioorg. & Med. Chem."},{"key":"10.1016\/j.phrs.2026.109664_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400109","article-title":"Folate-PEG-PROTAC Micelles for Enhancing Tumor-Specific Targeting Proteolysis In Vivo","volume":"13","author":"Ma","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2026.109664_bib160","doi-asserted-by":"crossref","first-page":"9374","DOI":"10.1038\/s41467-025-64426-7","article-title":"Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib161","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cej.2024.153437","article-title":"Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy","volume":"495","author":"Gao","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.phrs.2026.109664_bib162","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109664_bib163","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.109664_bib164","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1021\/jacs.5c00131","article-title":"Dual-Action-Only PROTACs","volume":"107","author":"Dutta","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib165","article-title":"Checkpoint Nano-PROTACs for activatable cancer photo-immunotherapy","volume":"35","author":"Chi","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.phrs.2026.109664_bib166","article-title":"PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy","volume":"39","author":"Xu","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.phrs.2026.109664_bib167","doi-asserted-by":"crossref","unstructured":"2020, C. Department of Molecular, Y.U. Developmental Biology, New Haven, CT, USA, C. Department of Molecular, Y.U. Developmental Biology, New Haven, CT, USA, D.o. Chemistry, Y.U. Pharmacology, New Haven, CT, USA, Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery, Cell. 181 (2020) 102\u2013114.","DOI":"10.1016\/j.cell.2019.11.031"},{"key":"10.1016\/j.phrs.2026.109664_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115775","article-title":"Rational modification of PROTACs for tumor-selective protein degradation","volume":"230","author":"Fu","year":"2026","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib169","article-title":"Revolutionizing protein degradation: harnessing nanoparticles for PROTAC delivery","volume":"37","author":"Fan","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.phrs.2026.109664_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104627","article-title":"Advances in computational methods for PROTAC drug discovery","volume":"31","author":"Martinez-Cort\u00e9s","year":"2026","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.phrs.2026.109664_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115927","article-title":"Enabling formulations for PROTACs: a line-of-sight to clinic","volume":"237","author":"Swedrowska","year":"2026","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.109664_bib172","doi-asserted-by":"crossref","first-page":"27382","DOI":"10.1021\/jacs.4c06402","article-title":"ClickRNA-PROTAC for tumor-selective protein degradation and targeted cancer therapy","volume":"146","author":"Teng","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.109664_bib173","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/s41467-025-57191-0","article-title":"Non-invasive in vivo monitoring of PROTAC-mediated protein degradation using an environment-sensitive reporter","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:17:51Z","timestamp":1793693871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826015793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":173,"alternative-id":["S1043661826015793"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109664","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo fate-guided design of efficient delivery systems for PROTACs: From molecular rationales to clinical progress","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109664"}}